A randomized, placebo-controlled, crossover trial of danazol for the treatment of premenstrual syndrome

Philip M. Hahn, P M Hahn, D A Van Vugt, Dean A. Van Vugt, R L Reid, Robert L. Reid
Psychoneuroendocrinology · 1995 · vol. 20(2) , pp. 193–209 · doi:10.1016/0306-4530(94)00053-d · PMID:7899538 · W2088259401
RCT OA: closed CC0 ⤵ 4 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This randomized, placebo-controlled, crossover trial evaluated danazol's efficacy in treating premenstrual syndrome symptoms.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

To investigate whether danazol is more effective than placebo for the treatment of premenstrual syndrome (PMS), we conducted a randomized, double-blind, crossover study comparing three successive cycles of danazol (200 mg bid) to three cycles of placebo. Thirty-one women meeting rigorous criteria for a diagnosis of severe PMS over two pretreatment cycles were enrolled; 28 of these subjects completed at least one cycle of treatment with symptom recordings, which were entered into the analysis. A significant period effect confounded the planned within-subject analysis and therefore, the main treatment comparisons were confined to the first period only. Symptom scores on the Premenstrual Tension Self-Rating Scale (PMTS), Beck Depression Inventory (BDI), and a Visual Analogue Scale (VAS) were compared for the premenstrual week in the last cycle of treatment. For the 16 patients on danazol, scores on the PMTS decreased by an average of 14.0 (10.7) (standard deviation) points from a baseline of 25.4 (5.6) points. For the 12 patients on placebo, PMTS scores decreased by an average of 3.6 (9.5) points from a baseline of 23.5 (5.8) points (14.0 vs. 3.6; p = .0133, unpaired t-test). Seven (43.8%) of the subjects on danazol achieved a clinically relevant reduction of symptoms into the asymptomatic range (PMTS scores < or = 5) as compared to one (8.3%) of the subjects on placebo. Thus, danazol (200 mg bid) provided greater relief from severe PMS during the premenstrual week than did placebo.

My notes (saved in your browser only)

MeSH descriptors

Danazol Premenstrual Syndrome Adult Analysis of Variance Anxiety Anxiety Anxiety Cross-Over Studies Danazol Danazol Depression Depression Depression Double-Blind Method Female Humans Menstrual Cycle Menstrual Cycle Middle Aged Patient Compliance

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (46)

Cited by (4)

Source provenance

openalex
last seen: 2026-05-11T05:39:31.692385+00:00
pubmed
last seen: 2026-10-08T21:59:07.256998+00:00
unpaywall
last seen: 2026-10-13T06:25:51.201866+00:00
License: CC0 · commercial use OK